News - Appointments

Malene Jensen has been appointed head of clinical development at Medivir AB to lead development of the Swedish company’s drug portfolio.

Motlalepula Matsabisa, a professor at the University of the Free State in South Africa, has been chosen by the World Health Organization to lead a new group to oversee research and clinical trials for the application of traditional medicines to treat Covid-19.

AstraZeneca Plc has appointed Aradhana Sarin as chief financial officer subject to the closing of the company’s acquisition of Alexion Pharmaceuticals, a US specialty pharmaceutical company. Dr Sarin is currently CFO at Alexion.

Joep Muijrers has joined Gilde Healthcare in the Netherlands to lead the firm’s investments in publicly-traded companies in the life sciences sector.

Klaus Edvardsen, an experienced oncology executive, has been appointed chief development officer at CureVac NV, effective 1 August 2021. He will be joining from Merck KGaA where he has led early and late-stage global oncology development.

Nanobiotix SA has appointed Bart Van Rhijn as its new chief financial officer as the company prepares for a registration study of its radioenhancer for patients with head and neck cancer.

France-based Onxeo SA has created a scientific advisory committee composed of five leading cancer experts to help it oversee development of drugs targeting tumour DNA damage response.

Venkat Reddy has been promoted to the position of chief executive of Macrophage Pharma Ltd from chief scientific officer as the company advances its small molecule compounds targeting inflammation, autoimmune disease and cancer.

Greg Madison, an experienced executive with specific knowledge about iron deficiency, has been appointed chief executive of Shield Therapeutics Plc, effective 1 June. Shield is making preparations for the launch of the iron deficiency product Accrufer in the US.

Sweden-based Betagenon AB has appointed James Hall as its new chief executive officer, and Gunnar Olsson as chairman of the board of directors as it advances the development of new therapies for metabolic disorders.